Ferry Ossendorp studied Biology and obtained his PhD degree in 1989 at the Netherlands Cancer Institute, University of Amsterdam. Postdoctoral research was carried out in the Immunology Division at the Netherlands Cancer Institute till 1992. Since 1993 started as a senior scientist in the department of Immunology in LUMC. Since 1996 he is scientific staff member of the department and group leader. He became Associate Professor in 2005 and Full Professor in 2010. Ferry Ossendorp has currently published 162 peer-reviewed publications and is inventor on five patents involving potentiation of cancer vaccines. Since 2013 he is Scientific board member of Dutch Cancer Foundation KWF.
The research of Ossendorp focuses on fundamental and translational tumor immunology. Immune therapeutic strategies in several animal models are studied, including T cell immunity, antigen processing and presentation, dendritic cell biology and the role of the tumor microenvironment. The role of T helper and regulatory cell types and the effects of several dendritic cell-modulating agents like Toll-like receptor ligands on the CD8 immune response are subjects of study. Combination therapies applying chemo- or photodynamic therapy and modulation of the tumor microenvironment with checkpoint blocking antibodies are studied in our preclinical models.
Dedicated design of molecular defined cancer vaccines which has resulted in clinical translation. Several antigen systems including model antigens, oncogenic viruses and neoantigens are studied. Optimization of vaccine delivery systems include dendritic cell targeting by biodegradable nanoparticles, Toll like receptor ligands and defined DNA vaccines. Peptide-based T cell vaccines conjugated to chemically well-defined TLR ligands have been in-house GMP produced and currently explored for immunotherapeutic treatment of cancer patients.